MTOR and gastric cancer: In gastric cancer, 30–60% of patients exhibit excessive activation of the PI3K–AKT–mTOR signalling pathway, which is derived from the amplifications of AKT, the loss of PTEN, or the mutations and amplifications of PIK3CA [38].